Animal models of pulmonary hypertension: Role in translational research

Drug Discovery Today: Disease Models

Volumn 7, Issue 3-4, 2010, Pages 89-97

  Pak, Oleg ^a   Janssen, Wiebke ^b   Ghofrani, Hossein Ardeschir ^a   Seeger, Werner ^a,b   Grimminger, Friedrich ^a   Schermuly, Ralph Theo ^a,b   Weissmann, Norbert ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 63 252; BLEOMYCIN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); IMATINIB; MONOCROTALINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RHO KINASE INHIBITOR; RIOCIGUAT; SEMAXANIB; SILDENAFIL; SIMVASTATIN; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CONGESTIVE HEART FAILURE; DISEASE MODEL; FUNCTIONAL ASSESSMENT; HUMAN; HYPOXEMIA; LUNG BLOOD VESSEL; LUNG EMBOLISM; LUNG RESECTION; NONHUMAN; PERSISTENT PULMONARY HYPERTENSION; PULMONARY HYPERTENSION; TRANSLATIONAL RESEARCH;

EID: 79958697718     PISSN: 17406757     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2011.02.002     Document Type: Review

References (49)

1. V.V. McLaughlin ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol. 53 2009 1573 1619
2. S. Schroll Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan Respir. Physiol. Neurobiol. 170 2010 32 36
3. R.T. Schermuly Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Eur. Respir. J. 32 2008 881 891
4. H. Beppu BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia Am. J. Physiol. Lung Cell Mol. Physiol. 287 2004 L1241 L1247
5. M.K. Steiner Interleukin-6 overexpression induces pulmonary hypertension Circ. Res. 104 2004 236 244 28p
6. S. Greenway S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy Am. J. Pathol. 164 2004 253 262 (Pubitemid 38364609)
7. S. Bonnet An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension Circulation 113 2006 2630 2641 (Pubitemid 43948012)
8. C. Guignabert Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension Circ. Res. 98 2006 1323 1330 (Pubitemid 43948088)
9. M. Mittal Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature Circ. Res. 101 2007 258 267 (Pubitemid 47344075)
10. M. McGuire, and A. Bradford Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats Eur. Respir. J. 18 2001 279 285 (Pubitemid 32776402)
11. J.L. Wright Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig J. Appl. Physiol. 100 2006 672 678 (Pubitemid 43671624)
12. B. Rondelet Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension Circulation 107 2003 1329 1335 (Pubitemid 36314419)
13. J. Schnader Chronic pulmonary hypertension in sheep: temporal progression of lesions J. Surg. Res. 62 1996 243 250 (Pubitemid 26142418)
14. R. Steinhorn Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophosphate (GMP) in pulmonary vasorelaxation Semin. Perinatol. 21 1997 393 408 (Pubitemid 27459488)
15. J. Jasmin Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan Cardiovasc. Res. 58 2003 621 631 (Pubitemid 36694448)
16. P.B. Sehgal Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques Am. J. Physiol. Lung Cell Mol. Physiol. 297 2009 L729 L737
17. A. Crosby Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis Am. J. Respir. Crit. Care Med. 181 2010 279 288
18. J. Zagorski Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres J. Immunol. 171 2003 5529 5536 (Pubitemid 37432843)
19. N. Sommer Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms Eur. Respir. J. 32 2008 1639 1651
20. N. Weissmann Hypoxia in lung vascular biology and disease Cardiovasc. Res. 71 2006 618 619 (Pubitemid 44848017)
21. R.T. Schermuly Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy Circulation 115 2007 2331 2339 (Pubitemid 46685901)
22. R.T. Schermuly Reversal of experimental pulmonary hypertension by PDGF inhibition J. Clin. Invest. 115 2005 2811 2821 (Pubitemid 41434408)
23. S.H. Zaidi Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension Circulation 105 2002 516 521 (Pubitemid 34141711)
24. T.M. Bull Gene expression profiling in pulmonary hypertension Proc. Am. Thorac. Soc. 4 2007 117 120 (Pubitemid 46067570)
25. O. Platoshyn Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes Am. J. Physiol. Lung Cell Mol. Physiol. 280 2001 L801 L812
26. K.R. Stenmark Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure Am. J. Physiol. Lung Cell Mol. Physiol. 297 2009 L1013 L1032
27. D.L. Burke Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment Am. J. Physiol. Lung Cell Mol. Physiol. 297 2009 L238 L250
28. L. Taraseviciene-Stewart Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J. 15 2001 427 438 (Pubitemid 32141434)
29. J.J. Lalich, and L. Merkov Pulmonary arteritis produced in rat by feeding Crotalaria spectabilis Lab Invest. 10 1961 744 750
30. G. Marsboom, and S. Janssens Models for pulmonary hypertension Drug Discover Today: Disease Models 1 2004 289 296 (Pubitemid 41132153)
31. K.R. Stenmark Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension Am. J. Physiol. 248 1985 H859 H866
32. P. Dorfmuller Inflammation in pulmonary arterial hypertension Eur. Respir. J. 22 2003 358 363 (Pubitemid 36987011)
33. K. Okada Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension Am. J. Pathol. 151 1997 1019 1025 (Pubitemid 27424311)
34. R. Dumitrascu Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury BMC. Pulm. Med. 8 2008 25
35. W. Raoul Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice Respir. Res. 8 2007 8
36. A. Molteni Monocrotaline pneumotoxicity in mice Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 57 1989 149 155 (Pubitemid 19170570)
37. M.B. Starling Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (PGI2) Prostaglandins Med. 3 1979 105 117 (Pubitemid 10225535)
38. R.J. Barst A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N. Engl. J. Med. 334 1996 296 302
39. S.T. Bonvallet BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats Am. J. Physiol. 266 1994 H1327 H1331
40. X. Jais Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial J. Am. Coll. Cardiol. 52 2008 2127 2134
41. L. Zhao Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428 (Pubitemid 32678272)
42. N. Galie Sildenafil citrate therapy for pulmonary arterial hypertension N. Engl. J. Med. 353 2005 2148 2157 (Pubitemid 41653106)
43. T. Nishimura Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats Am. J. Respir. Crit. Care Med. 166 2002 1403 1408 (Pubitemid 35292709)
44. M.R. Wilkins Simvastatin as a treatment for pulmonary hypertension trial Am. J. Respir. Crit. Care Med. 181 2010 1106 1113
45. H.A. Ghofrani Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Eur. Respir. J. 36 2010 792 799
46. H.A. Ghofrani Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy Am. J. Respir. Crit. Care Med. 182 2010 1171 1177
47. M. Klein Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling Circulation 118 2008 2081 2090
48. M. Gomberg-Maitland A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension Clin. Pharmacol. Ther. 87 2010 303 310
49. B.K. Dahal Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Eur Respir J. 36 2010 808 818